AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deAUG 112 min read$RNXT

RenovoRx, Inc.: RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) said it has completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. Trial enrollment is closing as of Aug. 7, 2026, with completion expected in 1H 2027 after 86 deaths events, and 78 events reported as of Aug. 11. Initial top-line data is expected in 2H 2027; primary endpoint is overall survival.

Original reporting
finanznachrichten.de
Published Aug 11, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$RNXT
Bullish
medium confidence
Mentioned
$RNXT
Relevance
7/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$RNXTBullishMed
01

Why it matters

Completion of enrollment is a meaningful execution milestone for the Phase III TIGeR-PaC trial, shifting focus to event accumulation (86 deaths) and eventual overall survival top-line data in 2H 2027.

02

Market read

Traders can update RNXT’s clinical timeline and probability-weighted risk profile based on enrollment closure and the remaining event count to the primary endpoint.

03

What to watch

The article does not provide interim efficacy metrics, safety signals, or event-rate expectations beyond the event count, so timing risk to the 2027 readout remains.

Relevance 7/10Novelty 7/10Timing: today, pre-2027 catalyst setting for Phase III top-line timing

Background

RenovoRx is developing a drug-device combination using its FDA-cleared RenovoCath device to deliver intra-arterial gemcitabine via its TAMP platform in locally advanced pancreatic cancer.

Company-level read

Ticker impact

$RNXTBullishMedium confidence
Context

RenovoRx says Phase III TIGeR-PaC enrollment is complete, with 78 of 86 death events reached and top-line data expected in 2H 2027.

Expected impact

Near-term upside bias on execution milestone, with volatility likely to fade until interim signals or the 2H 2027 top-line readout.

Evidence & confidence

The article provides a concrete operational milestone (closing enrollment) and a defined event-based timeline (86 events, 78 observed), which can move biotech risk perception even without efficacy results yet.

Market effects

Sector

Supports sentiment for drug-device oncology platforms and locoregional delivery approaches in pancreatic cancer.

Regional

Limited, primarily US biotech sentiment tied to Nasdaq-listed RNXT.

Global

Moderate, as pancreatic cancer trial progress can influence global investor appetite for similar delivery technologies.

Counterpoint

What could challenge this read

Enrollment completion does not confirm efficacy; investors may discount the milestone until survival outcomes are reported after the 86-event threshold.

Key entities

  • company
    RenovoRx, Inc.

    Nasdaq-listed life-sciences company developing targeted oncology therapies and commercializing RenovoCath.

  • clinical_trial
    TIGeR-PaC trial

    Phase III randomized multi-center trial in locally advanced pancreatic cancer with overall survival as the primary endpoint.

  • medical_device
    RenovoCath

    FDA-cleared drug-delivery device used for intra-arterial administration in the trial.

  • therapy
    Intra-arterial gemcitabine (IAG)

    Investigational drug-device combination candidate delivered via RenovoCath.

Read at source← All news

Related articles

AUG 31
$RNXTLow

Biotech Stocks At 52-Week Highs - RNXT +12%, BLSM, RVTY, ATRC, BFRI

Several biotech stocks hit 52-week highs on August 28, 2026. RenovoRx (RNXT) rose 12% to $1.68 after positive Phase 3 trial data. BlossomHill (BLSM) reached $20.61, with FDA Fast Track designation for BH-30643. AtriCure (ATRC) hit $49.98, reporting Q2 revenue of $153.6M. Biofrontera (BFRI) climbed to $1.61 with 32.9% product revenue growth. Revvity (RVTY) reached $130.07, raising full-year revenue guidance to $2.83B-$2.86B.

rttnews.com2 min
AUG 25
$RNXTMedAI 8/10

RenovoRx study: About 51% of a chemotherapy drug was extracted at the tumor site

RenovoRx (RNXT) reported peer-reviewed data showing ~51% local drug extraction at the tumor site in a sub-study of its Phase III TIGeR-PaC trial. The study compared intra-arterial gemcitabine (IAG) with intravenous gemcitabine (IVG) in 16 patients with locally advanced pancreatic cancer. IAG resulted in lower systemic exposure and a significant correlation between dFdU levels and CA 19-9 tumor marker reduction. The company reported $1.1M in 2025 sales and $909,000 in Q2 2026 revenue. The stock d

stocktitan.net3 min
AUG 14
$RNXTMed

RenovoRx Q2 Earnings Call Highlights

RenovoRx (NASDAQ:RNXT) reported Q2 gross profit of $766,000 and ~84% gross margin. Operating loss was ~$3.4M and net loss per share was $0.06. Cash fell to ~$9.5M at June 30. The company narrowed FY2026 revenue guidance to $3.75M-$4.25M and expects cash-flow break-even in Q4 2027. Phase III TIGeR-PaC enrollment is complete; initial data expected H2 2027.

yahoo.com6 min
AUG 13
$RNXTMedAI 8/10

RenovoRx (RNXT) Q2 2026 Earnings Call Transcript

RenovoRx (RNXT) reported Q2 2026 revenue of $909,000, up 115% year over year, and raised full-year 2026 guidance to $3.75 million to $4.25 million. The company said it completed Phase III TIGeR-PaC enrollment, had 78 survival events vs 86 required, and expects initial results in H2 2027. Cash was $9.5 million at June 30, 2026.

fool.com6 min
MAY 28
$RNXTMedAI 9/10

RenovoRx Says FDA Grants Orphan Drug Status For Oxaliplatin To Treat Pancreatic Cancer

RenovoRx said the FDA granted orphan drug designation for oxaliplatin to treat pancreatic cancer. The company said it is its second such designation in pancreatic cancer and third overall, supporting its RenovoCath targeted intra-arterial delivery approach. RenovoRx previously received ODD for intra-arterial gemcitabine via RenovoCath. In pre-market trading, RNXT was $0.93.

rttnews.com3 min